Faced with this judgment, the laboratory reassures: alternatives exist.
The Astrazeneca laboratory announces the cessation of the marketing of its oral antidiabetic in French pharmacies. This decision, motivated by “commercial considerations”, absolutely does not call into question the efficiency, tolerance or quality of manufacture of the drug, according to the mail addressed to health professionals on July 15 by the laboratory, quoted by the daily life of the pharmacist. This is important information for patients with type 2 diabetes currently under this treatment.
Patients concerned are strongly encouraged to consult their attending physician without delay. This approach will make it possible to discuss alternative therapeutic options and ensure a smooth transition to a new treatment adapted to their individual situation. The objective is to guarantee the continuity and efficiency of the management of their diabetes. This marketing stop is planned from January 30, 2026: it must therefore be anticipated now.
This is the 2.5 mg/1,000 mg (saxagliptin/chlorhydrate of Metformin (type 2 saxaglipliptin/chlorhydrates) medication that the disease is not sufficiently controlled by metformin alone or in combination with other antidiabetics. Faced with this judgment, the laboratory reassures: alternatives exist. The saxagliptin alone, present in Komboglyze, remains available under the names of Onglyza and its generics. This solution could be envisaged by certain patients, potentially adjusting their treatment.
Although the exact number of people under Komboglyze in France is not publicly known, this announcement directly impacts a fraction of millions of French people living with type 2 diabetes. It is crucial for the general public to understand that this decision is commercial and not linked to a security problem, in order to avoid unnecessary concern.
